Evidence map›Paper›PMID 33620694›Full record

ReviewAdvances in therapy2021

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes.

Neil Skolnik, Stefano Del Prato, Lawrence Blonde, Gagik Galstyan, Julio Rosenstock

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Neil SkolnikSidney Kimmel Medical College, Thomas Jefferson University, Abington Jefferson Health, Abington, PA, USA. nskolnik@comcast.net.ORCID 0000-0002-5085-4771
Stefano Del PratoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Lawrence BlondeDepartment of Endocrinology, Ochsner Medical Center, Frank Riddick Diabetes Institute, New Orleans, LA, USA.
Gagik GalstyanDiabetic Foot Department, Endocrinology Research Center, Moscow, Russia.
Julio RosenstockDallas Diabetes Research Center at Medical City, Dallas, TX, USA.
Dallas Diabetes Research Center · USEndocrinology Research Center · RUOchsner Medical Center · USThomas Jefferson University · USUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA

Indexed as

Diabetes Mellitus, Type 2HypoglycemiaDrug CombinationsGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineDrug CombinationsGlycated HemoglobinHypoglycemic AgentsInsulin GlargineFixed-ratio combinationGLP-1 RAGlycemic controlInsulin therapyType 2 diabetes

Identifiers

PMID33620694
PMCPMC8004501
OpenAlexW3130743117

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.